Español 
Deutsch 
Français 
MSCI World Index (MSC)
NASDAQ Composite (NASDAQ)
FTSE China A50 Index (FGI)
STOXX Europe 600 (SIX)
Nikkei 300 (OSA)
NIFTY 50 (NSE)
DAX Performance Index (XETRA)
FTSE 100 (FGI)
CAC 40 (EURONEXT)
Verici Dx plc (VRCDF)
Penarth, GB
Verici Dx plc is an immuno-diagnostics developer primarily dedicated to innovations within the kidney transplantation field. It creates both prognostic (predictive) and diagnostic (identifying current conditions) assays specifically designed for kidney transplant recipients. Its developmental pipeline currently features several key tests: Clarava, a pre-transplant prognostic tool designed to assess the risk of early acute rejection. Tuteva, a post-transplant solution focused on identifying acute cellular rejection. Protega, a novel liquid biopsy that aims to predict the future risk of fibrosis and long-term graft failure. Established in 2020, the company operates from its base in Penarth, United Kingdom.
No mergers or acquisitions recorded for this company.
| Indicator | 1D | 1W | 2W | 3W | 1M |
|---|
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| +0.00% | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% | -90.00% | -98.14% | -98.85% | -98.85% | -98.85% |
Revenue flow
Revenue by geography
Revenue by segment
Revenue composition
By product
By geography
Income Statement
Balance Sheet
Cash Flow Statement
Key Metrics
Financial Ratios
Employees
Financial Growth (CAGR)
Market Data
DCF figures are point estimates: small changes in growth or discount-rate assumptions move them materially. Read them as a reference, not a precise target.
-
Revenue growth Medical - Diagnostics & Research: +7.9%+12.2% ★ Q4'25: +254.4% (vs Q4'23)
-
EPS growth Medical - Diagnostics & Research: +30.8%+64.4% ★ Q4'25: +87.4% (vs Q4'23)
-
FCF margin FCF growth · Medical - Diagnostics & Research: +32.2%-227.1% Q4'25: -262.5% (vs Q4'23)
-
EBIT margin Medical - Diagnostics & Research: +9.6%-185.2% Q4'25: -215.7% (vs Q4'23)
-
ROIC Medical - Diagnostics & Research: +5.2%-206.2% Q4'25: -451.8% (vs Q4'23)
-
Share dilution Medical - Diagnostics & Research: 0.0%+242.8% Q4'25: +786.8% (vs Q4'23)
-
Debt / EBITDA Net debt/EBITDA · Medical - Diagnostics & Research: -0.13×-0.03× Q4'25: -0.01× (vs Q4'23)
* These projections are based on analyst consensus estimates and user-defined valuation multiples. This table is for informational purposes only and does not constitute a recommendation to buy or sell any security. Past performance is not indicative of future results.
| Metric |
Dec 2022 actual |
Dec 2023 actual |
Dec 2024 actual |
Dec 2025 actual |
|---|---|---|---|---|
| Revenue |
—
est: 66.7K (-100.0%)
|
1.01M
est: 1.00M (+1.3%)
|
3.34M
est: 3.25M (+2.7%)
|
3.75M
est: 3.80M (-1.4%)
|
| EBITDA |
-10.57M
est: 33.4K (-31,783.6%)
|
-7.88M
est: 500.0K (-1,675.2%)
|
-5.15M
est: 650.0K (-892.5%)
|
-6.36M
est: 760.0K (-936.2%)
|
| EBIT |
-11.19M
est: 33.4K (-33,667.7%)
|
-8.71M
est: 500.0K (-1,841.0%)
|
-5.85M
est: 650.0K (-1,000.3%)
|
-6.94M
est: 760.0K (-1,012.6%)
|
| Net Income |
-11.41M
est: -12.54M (+9.0%)
|
-8.73M
est: -11.62M (+24.8%)
|
-5.87M
est: -21.37M (+72.5%)
|
-7.09M
est: -7.04M (-0.7%)
|
| SGA |
10.50M
est: 191.6K (+5,379.9%)
|
8.60M
est: 2.87M (+199.4%)
|
8.71M
est: 9.16M (-4.9%)
|
8.11M
est: 10.71M (-24.3%)
|
| EPS |
-0.07
est: -0.07 (+5.9%)
|
-0.05
est: -0.05 (-2.7%)
|
-0.03
est: -0.03 (+6.7%)
|
-0.01
est: -0.01 (-0.8%)
|
Owner Earnings
Ownership Overview
Ownership breakdown not available.
No beneficial ownership filings recorded.
Institutional Activity (13F)
Institutional history not available.
Top holders not available.
ETF Ownership
This company is not held by any ETF in our universe.
Insider Activity
No insider activity available.
Insider history not available.
No recent insider transactions.
Executive team
Executive compensation
Executive compensation not available.
No CEO compensation history available.
Proxy statements
No proxy statements available for this company yet.
Recent SEC filings
No SEC filings available for this company yet.
Executive team
| Name | Title | Compensation | Gender |
|---|---|---|---|
| Sara jane Barrington | Chief Executive Officer & Executive Director | 383.4K | female |
| David Anderson | Chief Financial Officer & Company Secretary | — | male |
| Keith Gilliard | Senior Director of Sales | — | — |
No data available for this company.
No Senate trading activity found for this company.
No House trading activity found for this company.
Share your view on this stock and instantly see how the community has voted over the last 6 months.
Community Opinion for VRCDF
Short-term intention
Target Price Distribution
These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.
